FDA clears Lumipulse G CA19-9-N assay
Feb. 21, 2020—Fujirebio Diagnostics received FDA clearance of its Lumipulse G1200 CA19-9-N chemiluminescent enzyme immunoassay for use on the Lumipulse G1200 system.
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
CE-IVD approved Therascreen PIK3CA dx launched in Europe
Feb. 21, 2020—Qiagen announced the CE marking and launch of its Therascreen PIK3CA RGQ PCR Kit in Europe as an aid in identifying breast cancer patients with a PIK3CA mutation. The Therascreen PIK3CA test was approved in 2019 by the FDA and launched as a companion diagnostic test for Piqray (alpelisib) in the U.S.
Thermo Fisher announces collaboration with NanoPin
Feb. 20, 2020—Thermo Fisher Scientific and NanoPin Technologies have entered into a collaborative relationship to advance blood-based infectious disease detection technology through the development of highly sensitive liquid chromatography-mass spectrometry–based workflows.
Orchard receives vendor honors from KLAS Enterprises
Feb. 19, 2020—KLAS Enterprises recognized Orchard Software as a leader in the laboratory marketplace in its 2020 Best in KLAS awards.
Randox introduces test for COVID-19
Feb. 19, 2020—Randox Laboratories has introduced a test for the COVID-19 strain of coronavirus and nine other respiratory viruses.
Agilent introduces SureSelect DNA Kit
Feb. 18, 2020—Agilent Technologies introduced the SureSelect XT HS2 DNA Kit, designed to address key challenges that laboratories encounter when preparing DNA sequencing libraries for their research.
FDA issues EUA for first 2019 novel coronavirus diagnostic
Feb. 14, 2020—The FDA issued an emergency use authorization to enable emergency use of the Centers for Disease Control and Prevention’s 2019-nCoV Real-Time RT-PCR Diagnostic Panel.
BD, Babson partner to enable blood collection in retail settings
Feb. 14, 2020—Becton Dickinson and Babson Diagnostics, a diagnostic blood testing company, announced a long-term strategic partnership agreement to bring laboratory-quality, small-volume blood collection to retail pharmacies.
Access PCT cleared by the FDA
Feb. 13, 2020—Beckman Coulter’s Access PCT assay has received FDA 510(k) clearance and is available for sale in the United States.
Siemens adds ARK Fentanyl Assay to its testing menu
Jan. 27, 2020—Siemens Healthineers has added the ARK Fentanyl Assay to its testing menu.